Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Ghent

Pulmonary Disease West Columbia, SC Medical Doctor

NPI 1528022423 CMS profile 69063

2728 Sunset Blvd, West Columbia, SC 29169

Open in the dashboard

General payments

$12,050

616 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Ghent of West Columbia, SC is reported in the CMS Open Payments database as having received $12,050 across 616 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,501 104
2024 General $2,070 92
2023 General $2,218 108
2022 General $1,726 100
2021 General $282 18
2020 General $630 36
2019 General $2,623 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Ghent
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William Ghent were reported at $2,501. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William Ghent Pulmonary Disease median Middle half National median
2019 $2,623 $377 $109–$1,340 $163
2020 $630 $230 $56–$907 $114
2021 $282 $269 $68–$1,072 $132
2022 $1,726 $390 $100–$1,457 $149
2023 $2,218 $419 $114–$1,659 $160
2024 $2,070 $476 $123–$1,818 $164
2025 $2,501 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,491 155 payments
  2. AstraZeneca Pharmaceuticals LP $2,278 100 payments
  3. Genzyme Corporation $905 31 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $894 51 payments
  5. Regeneron Healthcare Solutions, Inc. $864 29 payments
  6. United Therapeutics Corporation $507 19 payments
  7. Insmed, Inc. $490 29 payments
  8. Actelion Pharmaceuticals US, Inc. $427 22 payments
  9. Sunovion Pharmaceuticals Inc. $333 24 payments
  10. Genentech USA, Inc. $265 16 payments
  11. Other $2,598 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,982 610 payments
  2. Education $68 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,479 96 payments
  2. DUPIXENT Immunology $855 28 payments
  3. NUCALA $771 41 payments
  4. FASENRA $708 28 payments
  5. DUPIXENT Inflammation And Immunology $681 24 payments
  6. AIRSUPRA $537 20 payments
  7. Arikayce $490 29 payments
  8. OPSUMIT $392 20 payments
  9. UPTRAVI $383 20 payments
  10. BREZTRI $364 18 payments
  11. Other $6,987 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,865

Median for Pulmonary Disease: 936

Drug cost

$2,460,318

Median for Pulmonary Disease: $487,987

Branded share of claims

79.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 56 $743,797
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 682 $581,489
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 206 $153,701
Spiriva Respimat Tiotropium Bromide Brand 167 $129,196
Nucala Mepolizumab Brand 25 $123,489
Breo Ellipta Fluticasone/Vilanterol Brand 227 $118,941
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 102 $75,765
Ambrisentan Generic 11 $71,662
Symbicort Budesonide/Formoterol Fumarate Brand 185 $65,548
Pirfenidone Generic 22 $60,827

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$214,763

Of which drugs: $1,969

Medicare patients

1,329

Average age 74

Services billed

3,866

702 women, 627 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 43%
COPD 37%
Diabetes 36%
Chronic kidney disease 24%
Atrial fibrillation 23%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 17 17 $1,381

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $212
  • GENZYME CORPORATION $172
$384 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $320
$320 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $210
$210 682 —
NUCALA
  • GlaxoSmithKline, LLC. $202
$202 25 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

616 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record